|本期目录/Table of Contents|

抗血管生成药物治疗恶性脑水肿的研究进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3736-3742
栏目:
综述
出版日期:
2019-09-08

文章信息/Info

Title:
Advances in the treatment of malignant brain edema with angiogenesis inhibitor
作者:
马晓云;?李全福;?姜彩虹;?陈 凤;?乌雅罕;?王文娟;?乌云高娃;?金高娃
内蒙古医科大学鄂尔多斯临床医学院 鄂尔多斯市中心医院肿瘤科,内蒙古 鄂尔多斯 017000
Author(s):
Ma Xiaoyun;?Li Quanfu;?Jiang Caihong;?Chen Feng;?Wu Yahan;?Wang Wenjuan;?Wu Yungaowa;?Jin Gaowa
Oncology Department,Ordos School of Clinical Medicine,Inner Mongolia Medical University,Ordos Central Hospital,Inner Mongolia Ordos 017000,China.
关键词:
脑水肿;?抗血管生成药物;?脑转移瘤
Keywords:
brain edema;?anti-angiogenesis;?brain metastases
分类号:
R739.41
DOI:
10.3969/j.issn.1672-4992.2019.20.044
文献标识码:
A
qq自动领红包软件:
抗血管生成药物通过减少血管通透性和血脑屏障破坏,能有效减轻恶性脑水肿,缓解临床症状,改善患者生命质量。目前多种抗血管生成药物在治疗恶性脑水肿方面取得了积极的疗效,因此被认为是较糖皮质激素治疗恶性脑水肿更为安全、有效的治疗手段。
Abstract:
Angiogenesis inhibitor can effectively reduce malignant brain edema,relieve clinical symptoms and improve the quality of life of patients by reducing vascular permeability and the blood-brain barrier damage.At present,a variety of angiogenesis inhibitors have achieved a positive effect in the treatment of malignant brain edema,so it is considered to be a more safe and effective treatment than glucocorticoid in the treatment of malignant brain edema.

参考文献/References

[1]Soffietti R,Abacioglu U,Baumert B,et al.Diagnosis and treatment of brain metastases from solid tumors:Guidelines from the European Association of Neuro-Oncology(EANO)[J].Neuro-Oncology,2017,19(2):162-174.
[2]Taillandier L,Blonski M,Darlix A,et al.Supportive care in neurooncology[J].Revue Neurologique,2011,167(10):762-772.
[3]Tsao MN,Khuntia D,Mehta MP.Brain metastases:What's new with an old problem[J]?Curr Opin Support Palliat Care,2012,6(1):85-90.
[4]Lukas RV,Gabikian P,Garza M,et al.Treatment of brain metastases[J].Oncology,2014,87(6):321-329.
[5]Hu WG,Weng YM,Dong Y,et al.Apatinib in refractory radiation-induced brain edema[J].Medicine,2017,96(46):e7358.
[6]Chinese Neurosurgical Society.Consensus on the drug treatment of peritumoral brain edema[J].Natl Med J China,2010,90(1):5-9.[中华医学会神经外科学分会.颅内肿瘤周围水肿药物治疗专家共识(第1版)[J].中华医学杂志,2010,90(1):5-9.]
[7]Murayi R,Chittiboina P.Glucocorticoids in the management of peritumoral brain edema:A review of molecular mechanisms[J].Child's Nervous System,2016,32(12):2293-2302.
[8]Hou J,Varun R Kshettry,Warren R Selman,et al.Peritumoral brain edema in intracranial meningiomas:The emergence of vascular endothelial growth factor-directed therapy[J].Neurosurg Focus,2013,35(6):1-10.
[9]Gerstner ER,Duda DG,di Tomaso E,et al.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer[J].Nat Rev Clin Oncol,2009,6(4):229-236.
[10]Dvorak HF.Vascular permeability factor/vascular endothelial growth factor:A critical cytokine in tumor angiogenesis and a potential target for fiagnosis and therapy[J].J Clin Oncol,2002,20(21):4368-4380.
[11]Jin XL,Liang B,Chen ZQ,et al.The dynamic changes of capillary permeability and upregulation of VEGF in rats following radiationinduced brain injury[J].Microcirculation,2014,1(2):171-177.
[12]Nonoguchi N,Miyatake S,Fukumoto M,et al.The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain:Pthological consideration of their potential roles[J].Journal of Neuro-Oncology,2011,105(2):423-431.
[13]WANG DP,SHEN XL,HE W,et al.Relations of expressions of hypoxia-inducible factor-1α and vascular endothelial growth factor-a with angiogenesis and pertumoral brain edema in meningiomas[J].Chin J Neuromed,2014,13(9):885-889.[王大鹏,沈晓黎,何伟,等.缺氧诱导因子1α、血管内皮生长因子A与脑膜瘤血管新生及瘤周脑水肿的关系[J].中华神经医学杂志,2014,13(9):885-889.]
[14]Reszec J,Hermanowicz A,Rutkowski R,et al.Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema[J].Biomed Research International,2015(2015):1-8.
[15]Nassehi D,Dyrbye H,Andresen M,et al.Vascular endothelial growth factor a protein level and gene expression in intracranial meningiomas with brain edema[J].APMIS,2011,119(12):831 -843.
[16]Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.
[17]Ferrara N,Adamis AP.Ten years of anti-vascular endothelial growth factor therapy[J].Nat Rev Drug Discov,2016,15(6):385-403.
[18]Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Research,2004,64(11):3731-3736.
[19]Clauss M.Molecular biology of the VEGF and the VEGF receptor family[J].Seminars in Trombosis and Hmostasis,2000,26(5):561.
[20]Roskoski R.A historical overview of protein kinases and their targeted small molecule inhibitors[J].Pharmacological Research,2015(100):1-23.
[21]Lee CS,Baek J,Han S.The role of kinase modulators in cellular senescence for use in cancer treatment[J].Molecules(Basel,Switzerland),2017,22(9):1411.
[22]Robinson DR,Wu YM,Lin SF.The protein tyrosine kinase family of the human genome[J].Oncogene,2000,19(49):5548-5557.
[23]Gocek E,Moulas AN,Studzinski GP.Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells[J].Crit Rev Clin Lab Sci,2014,51(3):125-137.
[24]Winkler F,Kozin SV,Tong RT,et al.Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:Role of oxygenation,angiopoietin-1,and matrix metalloproteinases[J].Cancer Cell,2004,6(6):553-563.
[25]Lee C,Heijn M,Di Tomaso E,et al.Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions[J].Cancer Res,2000,60(19):5565-5570.
[26]Braghiroli MI,Sabbaga J,Hoff PM.Bevacizumab:Overview of the literature[J].Expert Review of Anticancer Therapy,2014,12(5):567-580.
[27]Wadhwa R,Taketa T,Sudo K,et al.Ramucirumab:A novel antiangiogenic agent[J].Future Oncology,2013,9(6):789-795.
[28]Ciombor KK,Berlin J.Aflibercept-a decoy VEGF receptor[J].Curr Oncol Rep,2014,16(2):368.
[29]Gonzalez J,Kumar AJ,Conrad CA,et al.Effect of bevacizumab on radiation necrosis of the brain[J].Radiation Oncology Biol Phys,2007,67(2):323-326.
[30]Levin VA,Bidaut L,Hou P,et al.Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the CNS[J].Int J Radiat Oncol Biol Phys,2011,79(5):1487-1495.
[31]Dashti SR,Spalding A,Kadner RJ,et al.Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain[J].Journal of Neurosurgery Pediatrics,2015,15(1):20.
[32]Zhuang HQ,Yuan XK,Zheng Y,et al.A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis[J].Scientific Reports,2016,6(1):1-7.
[33]Berghoff AS,Saxa C,Kleinb M,et al.Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer:A case report[J].Breast Care,2014,9(2):134-136.
[34]Wang Y,Wang E,Pan L,et al.A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema[J].Journal of Neuro-Oncology,2014,119(2):369-376.
[35]Meng XY,Zhao RG,Shen G,et al.Efficacy and safety of bevacizumab treatment for refractory brain edema:Case report[J].Medicine,2017,96(44):e8280.
[36]Meng XY,Zhao RG,Ding LJ,et al.Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery:A case report[J].Cancer Biology & Therapy,2018,19(6):461-464.
[37]Shen G,Wang YJ,Guan YJ,et al.Relief effect of bevacizumab on severe edema induced by re-irradiation in brain tumor ratients[J].Chinese Medical Journal,2015,128(15):2126-2129.
[38]Sadraei NH,Dahiya S,Murphy ES,et al.Treatment of cerebral radiation necrosis with bevacizumab:The Cleveland clinic experience[J].Am J Clin Oncol,2015,38(3):304-310.
[39]Zhuang H,Yuan X,Chang JY,et al.Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation[J].Oncotarget,2016,7(30):48842-48849.
[40]YE CL,CHEN Y,LI Y,et al.The efficacy of low dose bevacizumab for cerebral radiation necrosis[J].Chin J Stereotact Funct Neurosurg,2016,29(02):90-93.[叶春林,陈勇,李勇,等.低剂量贝伐单抗治疗放射性脑坏死的临床疗效[J].立体定向和功能性神经外科杂志,2016,29(02):90-93.]
[41]SU J,QIAN Y,SHI KZ,et al.Clinical efficacy of bevacizumab for the treatment of serious peritumorous brain edema[J].Chin J Clin Oncol,2016,43(23):1045-1048.[苏进,钱莹,史克志,等.贝伐珠单抗治疗难治性瘤周脑水肿的近期疗效观察[J].中国肿瘤临床,2016,43(23):1045-1048.]
[42]ZHAO RG,MENG XY,SHEN G,et al.Efficacy analysis of bevacizumab in brain metastases patients with serious cerebral edema[J].Chin Clin Oncol,2016,21(03):233-237.[赵儒钢,孟祥颖,申戈,等.贝伐珠单抗治疗脑转移瘤难治性瘤周水肿的疗效分析[J].临床肿瘤学杂志,2016,21(03):233-237.]
[43]ZHANG HH,YUE W,FU Y,et al.Observation on clinical efficacy of bevacizumab in treatment of lung cancer brain metastasis complicated with refractory peritumoral edema[J].Journal of North Sichuan Medical College,2017,32(2):178-181.[张欢欢,岳文,付艳,等.贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效观察[J].川北医学院学报,2017,32(2):178-181.]
[44]DONG WJ,GONG MC,XIAO JJ,et al.Clinical observation of bevacizumab in the treatment of peritumoral brain edema in refractory brain metastases[J].Oncology Progress,2018,16(04):465-468.[董文静,宫满成,萧剑军,等.贝伐珠单抗治疗难治性脑转移瘤瘤周水肿的临床观察[J].癌症进展,2018,16(04):465-468.]
[45]Gordon MS,Margolin K,Talpaz M,et al.Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J].J Clin Oncol,2001,19(3):843-850.
[46]Zhang HJ.Apatinib for molecular targeted therapy in tumor[J].Drug Design,Development and Terapy,2015,9(11):6075-6081.
[47]Hu WG,Weng YM,Dong Y,et al.Apatinib in refractory radiation-induced brain edema[J].Medicine,2017,96(46):e7358.
[48]Song YQ,Liu BL,Guan M,et al.Successful treatment using apatinib in intractable brain edema:A case report and literatures review[J].Cancer Biology & Therapy,2018,19(12):1093-1096.
[49]Hu T,Liu CW,Li QH,et al.Apatinib+CPT-11+S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer[J].Medicine,2018,97(15):e349.
[50]LIU HL,RUAN P,PENG M,et al.Apatinib combined with brain radiotherapy in the treatment of atypical lung carcinoid brain metastases:A case report[J].Chin Clin Oncol,2018,23(05):476-478.[刘华丽,阮鹏,彭敏,等.阿帕替尼联合脑部放疗同步替莫唑胺治疗非典型肺类癌脑转移1例[J].临床肿瘤学杂志,2018,23(05):476-478.]
[51]DENG LC,LIU XW,ZENG J,et al.Osteosarcoma brain metastasis treated with apatinib:A case report[J].J Chin Oncol,2019,25(1):78-80.[邓立春,刘雄伟,曾洁,等.阿帕替尼治疗骨肉瘤脑转移1例[J].肿瘤学杂志,2019,25(1):78-80.]
[52]Aparicio-Gallego G,Blanco M,Figueroa A,et al.New insights into molecular mechanisms of sunitinib-associated side effects[J].Molecular Cancer Therapeutics,2011,10(12):2215-2223.
[53]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Research,2004,64(19):7099-7109.
[54]Kelly PJ,Weiss SE,Sher DJ,et al.Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma[J].J Clin Oncol,2010,28(25):e433-e435.
[55]Hill KL Jr,Adam C Lipson,Sheehan JM.Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma[J].J Neurosurg,2009,111(3):497-503.
[56]German Martín,Lorena Bellido,Cruz JJ.Reversible posterior leukoenceph-alopathy syndrome induced by sunitinib[J].J Clin Oncol,2007,25(23):3559.
[57]Li J,Al-Huniti N,Henningsson A,et al.Population pharmacokinetic and exposure simulation analysis for cediranib(AZD2171)in pooled phase I/II studies in patients with cancer[J].Br J Clin Pharmacol,2017,83(8):1723-1733.
[58]Kamoun WS,Ley CD,Farrar CT,et al.Edema control by cediranib,a vascular endothelial growth factor receptor-targeted kinase inhibitor,prolongs survival despite persistent brain tumor growth in mice[J].J Clin Oncol,2009,27(15):2542-2552.
[59]Batchelor TT,Sorensen AG,di Tomaso E,et al.AZD2171,a pan-VEGF receptor tyrosine kinase inhibitor,normalizes tumor vasculature and alleviates edema in glioblastoma patients[J].Cancer Cell,2007,11(1):83-95.
[60]Wadhwa R,Taketa T,Sudo K,et al.Ramucirumab:A novel antiangiogenic agent[J].Future Oncol,2013,9(6):789-795.
[61]Li J,Qin SK,Xu RH,et al.Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer:The FRESCO randomized clinical trial[J].JAMA,2018,319(24):2486-2496.
[62]Li B,Wu XY,Zhou H,et al.Acid-induced unfolding mechanism of recombinant human endostatin[J].Bioch Emistry,2004,43(9):B2550-2557.
[63]JIANG XD,DING MH,QIAO Y,et al.Preliminary clinical study of recombinant human endostatm combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer and the patients suitable for this therapy[J].Chin J Med & Brain Sci,2014,23(2):122-125.[蒋晓东,丁曼华,乔云,等.内皮抑素联合放疗治疗肺癌脑转移及其获益人群筛选的临床研究[J].中华行为医学与脑科学杂志,2014,23(2):122-125.]
[64]Jiang XD,Ding MH,Qiao Y,et al.Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases[J].Clinical Lung Cancer,2014,15(2):e23-e29.
[65]LIAO HY,ZHANG J,WU CX,et al.Effect of whole brain radiotherapy improved by endostatin in treatment of lung adenocarcinoma with multiple brain metastases[J].Academic Journal of Guangzhou Medical University,2017,45(03):27-30.[廖洪映,张健,伍传新,等.内皮抑素提高全脑放射治疗肺腺癌多发脑转移的疗效[J].广州医科大学学报,2017,45(03):27-30.]
[66]Jayson GC,Kerbel R,Ellis LM,et al.Antiangiogenic therapy in oncology:Current status and future directions[J].Lancet,2016,388(10043):518-529.
[67]Liu S,Kurzrock R.Toxicity of targeted therapy:Implications for response and impact of genetic polymorphisms[J].Cancer Treat Rev,2014,40(7):883-891.
[68]Izzedine H,Massard C,Spano JP,et al.VEGF signalling inhibition-induced proteinuria:Mechanisms,significance and management[J].Eur J Cancer,2010,46(2):439-448.
[69]Hapani S,Chu D,Wu S.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:A meta-analysis[J].Lancet Oncol,2009,10(6):559-568.
[70]Qi WX,Sun YJ,Tang LN,et al.Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors:A systematic review and meta-analysis[J].Critical Reviews in Oncology and Hematology,2013,89(3):394-403.
[71]Clemons J,Gao D,Naam M,et al.Thyroid dysfunction in patients treated with sunitinib or sorafenib[J].Clin Genitourin Cancer,2012,10(4):225-231.
[72]Martini M,de Pascalis I,D'Alessandris QG,et al.VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma[J].BMC Cancer,2018,18(1):553.
[73]Han K,Claret L,Piao Y,et al.Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs.chemotherapy alone in patients with first-line gastric cancer and elevated plasma VEGF-A[J].CPT Pharmacometrics Syst Pharmacol,2016,5(7):352-358.
[74]SHAO Y,ZHONG DS.Detection and clinical signifcance of abundance of EGFR mutation[J].Chin J Lung Cancer,2017,20(8):578-583.[邵宜,钟殿胜.EGFR突变丰度的检测及其临床意义[J].中国肺癌杂志,2017,20(8):578-583.]

备注/Memo

备注/Memo:
CSCO-先声抗肿瘤血管靶向治疗科研基金;北京医学奖励基金会肺癌医学青年专家委员会BEST基金(编号:YXJL-BEST-B-01)
更新日期/Last Update: 1900-01-01